首页> 外文期刊>Reproductive sciences >Gonadotropin-Releasing Hormone Analogs for Gonadal Protection During Gonadotoxic Chemotherapy: A Systematic Review and Meta-Analysis
【24h】

Gonadotropin-Releasing Hormone Analogs for Gonadal Protection During Gonadotoxic Chemotherapy: A Systematic Review and Meta-Analysis

机译:促毒性毒性化疗期间对促性腺保护的促性腺激素释放激素类似物:系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective: A systematic review and meta-analysis was conducted to investigate whether gonadotropin-releasing hormone analogs (GnRHa) have a protective role in women treated with alkylating agents. Data Sources: Major databases (PubMED, EMBASE, Cochrane Central Register of Controlled Trials), systematic snowballing, and trial registries were screened from the inception dates until September 2017. Methods and Study Selection Comparative studies involving reproductive-aged women undergoing chemotherapy with or without coadministration of GnRHa were included. Spontaneous menstrual resumption was assessed as a main outcome. Statistical analyses were performed with STATA 14.2 statistical software. Effect estimates were presented as risk ratios (RR) with 95% confidence intervals (CIs). Results: The literature search yielded 25 436 citations and 84 papers were assessed in full text. Eighteen studies (11 randomized controlled trials [RCTs] and 7 cohort studies) published between 1987 and 2015 were included in the analysis, revealing a significant protective effect of GnRHa (n = 1043; RR:1.38; 95% CI: 1.18-1.63) although with high heterogeneity (I-2 = 83.3%). Subgroup analyses revealed a significant benefit of GnRHa cotreatment both in RCTs and in cohort studies. Statistical significance was found in all subgroups by the underlying disease, that is, hematological malignancies, autoimmune diseases, and breast cancer. Sensitivity analyses in GnRH agonist-treated patients, in patients younger than 40 years old, and in patients without supradiaphragmatic radiotherapy also revealed a significant benefit of GnRHa cotreatment. Conclusion: Our results indicate that concurrent GnRHa administration is an effective method to decrease gonadotoxicity of alkylating agents. The presence of low-quality evidence favoring gonadoprotective effect requires a strong recommendation for offering GnRHa coadministration to young women who are to undergo gonadotoxic chemotherapy. Capsule: The present systematic review and meta-analysis shows a significant gonadoprotective effect of gonadotropin-releasing hormone analogs in women treated with alkylating agents.
机译:目的:进行系统审查和荟萃分析,以研究促进促性腺激素释放激素类似物(GNRHA)是否对烷基化剂处理的妇女具有保护作用。数据来源:主要数据库(受控试验的PubMed,Embase,Cochrane中央登记册),系统雪球和试验登记处被筛选到2017年9月。涉及在有或没有包括GNRHA的共同管理。自发月经恢复被评估为主要结果。统计分析与Stata 14.2统计软件进行。效果估算呈现为风险比(RR),置信区间95%(CIS)。结果:文献搜索产生了25个436引文,并在全文中评估了84篇论文。 1987年至2015年间公布的十八项研究(11例随机对照试验[RCTS]和7个队列研究)包括在分析中,揭示了GNRHA的显着保护作用(N = 1043; RR:1.38; 95%CI:1.18-1.63)虽然具有高异质性(I-2 = 83.3%)。亚组分析显示RCT在RCT和群组研究中的GNRHA COTREATEATEM的显着益处。在潜在疾病的所有亚组中发现了统计学意义,即血液恶性肿瘤,自身免疫疾病和乳腺癌。在40岁以下的患者中,GNRH激动剂治疗患者的敏感性分析,并且在没有超高射放疗的患者中也揭示了GNRHA COTREATEMMENT的显着效果。结论:我们的结果表明,同时的GNRHA施用是减少烷基化试剂的促毒性毒性的有效方法。有利于潮腺保护作用的低质量证据需要强有力的建议,为将GNRHA共同分配给要接受促性腺毒性化疗的年轻女性。胶囊:本发明的系统评价和荟萃分析显示了烷基化试剂治疗的妇女促促妇女促促妇女促释放的激素类似物的显着促进药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号